Several IL-36 inhibitors have been developed and phase II clinical trials of anti–IL-36 receptor antibody in patients with GPP and PPP are ongoing, suggesting that the latter may also offer a possibility for targeted therapy of acneiform skin toxicities caused by EGFR/MEK inhibition in the near future. This evidence concerns the gene IL1RL2 and palmoplantar pustulosis.